Australian Institute for Bioengineering and Nanotechnology AIBN

What Australian Institute for Bioengineering and Nanotechnology AIBN does

The Australian Institute for Bioengineering and Nanotechnology (AIBN) is a research institute within The University of Queensland, founded in 2002 and headquartered at UQ's St Lucia campus in Brisbane. AIBN operates 500+ researchers across 9 co-located NCRIS-funded facilities, including the National Biologics Facility (BASE — Australia's largest mRNA research supplier), the $70 million Biosustainability Hub for synthetic biology, the AMTAR radiopharmaceuticals hub with on-site cyclotron, and the Australian Organoid Facility. Its core technologies span the Molecular Clamp vaccine platform (which produced a COVID-19 vaccine candidate to Phase I clinical trials within six months), super fungi bioleaching for critical mineral recovery, gold nanoparticle diagnostics ('molecule chips'), quantum dot solar technology, snake venom hydrogel wound treatments, and spinifex-derived nanofiber biomaterials.

AIBN's business model is publicly funded research commercialization rather than commercial product sales. Revenue streams include Australian Research Council, NHMRC, and MRFF competitive grants; contract research with industry partners (Sanofi, Boeing, CSL, Dow, Woodside, Telix, AdvanCell, Evolution Mining, Redflow); technology licensing through UniQuest (UQ's commercialization arm); and equity participation in spinout companies (Vaxxas, Vicebio — acquired by Sanofi in 2025 for a billion-dollar deal, Cassowary Pharma). The institute's go-to-market is sales-led, with industry partnerships driven by direct engagement rather than traditional channel sales.

Customer segments span pharmaceutical and biotech (vaccines, therapeutics, diagnostics), mining and energy (sustainability, critical minerals, battery storage), aerospace and defense (antiviral surface coatings with Boeing), and advanced manufacturing (bio-based production). Partnerships with CEPI for pandemic preparedness, the US Department of Defense for wound healing technology, and the Queensland Government for translational science infrastructure support AIBN's role as a translational research platform bridging public funding and commercial application.

Name

Australian Institute for Bioengineering and Nanotechnology AIBN

Legal name

The University of Queensland

Website

https://aibn.uq.edu.au

Company type

Private

Operating status

Operating

Headcount range

101–250 employees

Short description

AIBN is a University of Queensland research institute with 500+ researchers operating 9 co-located NCRIS facilities, translating bioengineering and nanotechnology breakthroughs into vaccines, therapeutics, diagnostics, and sustainable industrial solutions for industry partners and government agencies.

Ownership category

akta.pro rank

Headquarters

HQ city

Brisbane

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

1. Research Funding (Government Grants): Major revenue streams include Australian Research Council (ARC) grants, National Health and Medical Research Council (NHMRC) Investigator Grants, and Medical Research Future Fund (MRFF) funding. Includes ARC Laureate Fellowships, Discovery Projects, and Centre of Excellence funding.
2. Industry Research Partnerships: Contract research services and collaborative research agreements with pharmaceutical companies (Sanofi, Vicebio, CSL), mining companies (Evolution), energy firms (Woodside, GE), and aerospace companies (Boeing). Revenue from research services, facility access fees, and collaborative project funding.
3. Technology Licensing: Intellectual property commercialized through UniQuest (UQ's commercialization company), including licensing of molecular clamp technology, vaccine platforms, and diagnostic technologies to biotech companies and pharmaceutical firms.
4. Spinout Companies: Creation and equity participation in spinout companies including Vaxxas (needle-free vaccine delivery), Vicebio (vaccines acquired by Sanofi for billion-dollar deal), and Cassowary Pharma (chronic pain treatments).

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Core offering

AIBN is an academic research institute that operates nine co-located NCRIS facilities conducting advanced bioengineering and nanotechnology research. It provides contract research services, facility access, technology licensing, and spinout commercialization in mRNA vaccines, radiopharmaceuticals, synthetic biology, nanomedicine, and advanced materials for industry partners and government clients.

Product overview

AIBN is a university research institute (not a product company) that operates specialized research facilities and develops technologies for translation with industry partners. The core offering consists of co-located NCRIS facilities including the Biosustainability Hub ($70M synthetic biology facility), BASE Facility (mRNA biologics), AMTAR (radiopharmaceuticals), and Australian Organoid Facility. Key technologies in development include the Molecular Clamp vaccine platform, Super Fungi bioleaching for mining remediation, snake venom hydrogel wound treatments, gold nanoparticle diagnostics, and advanced biofuels. AIBN works with over 100 industry partners to translate research from lab to clinic through facilities like the National Biologics Facility and specialized production labs with cyclotron and imaging equipment on-site.

Differentiator

Problem solved

Functional benefit

Brands

• BASE Facility: National Biologics Facility - biggest supplier of mRNA vaccines and therapies for research in Australia
• Biosustainability Hub
• AMTAR Hub
• Australian Organoid Facility (AOF)

Products and services

• Biosustainability Hub A $70 million synthetic biology facility offering industry partners a one-stop-shop for transforming production practices and creating carbon-neutral products and materials using automated synthetic biology.
• BASE Facility (National Biologics Facility) Australia's biggest supplier of mRNA vaccines and therapies for research, enabling AIBN researchers and industry partners to advance concepts into new medicines, therapies, or diagnostics. Has produced 40+ mRNA vaccines and therapies at 65mg each.
• ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals (AMTAR) A hub housing state-of-the-art target discovery, production facilities, radiobiology and radiochemistry labs, cyclotron, and imaging equipment enabling end-to-end translation of radiopharmaceuticals and theranostics for cancer therapies.
• Australian Organoid Facility (AOF) Facility that designs, grows, and supplies organoids for researchers and scientific institutes, scaling up organoid production capability for personalized medicine applications using stem cell technology.
• Molecular Clamp Platform Technology Second-generation vaccine platform technology enabling rapid generation of viral subunit vaccines that are safe, elicit optimal immune response, cost-effective, and thermally stable. Licensed exclusively to Vicebio (acquired by Sanofi in 2025).
• Rapid Response Vaccine Pipeline CEPI-funded pipeline safeguarding against future pandemics through the rapid production of safe and effective vaccines within accelerated timelines, capable of producing vaccine candidates within 6 months.
• Super Fungi Bioleaching Technology Engineered fungi strains that produce organic acids to detoxify mining tailings and recover valuable rare earth elements (vanadium, scandium) from mining waste through bioleaching using adaptive laboratory evolution.
• Snake Venom Hydrogel (BioBandage) A hydrogel wound treatment using proteins from eastern brown and saw-scaled viper venom to accelerate blood clotting, remaining liquid when cool but solidifying at body temperature to seal wounds.

Quantifiable outcome

• Produced COVID-19 vaccine candidate entering Phase I clinical trials within 6 months
• +5 more outcomes

Named customers10 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature11 records

Partnerships

22 partnerships are on record, tiered core and flagship.

• VaxxascoreStrategic or Co-development Partner · 1 January 2020Partnership worth AU$3.2 million prize to develop and distribute patch-based mRNA COVID-19 vaccine using Vaxxas's needle-free patch technology. AIBN provided vaccine development expertise while Vaxxas contributed their delivery platform.
• VicebioflagshipStrategic or Co-development Partner · 1 January 2019Contract research partnership for respiratory virus vaccine development using molecular clamp technology. Vicebio progressed RSV vaccine candidate (VXB-211) through preclinical development. Acquired by Sanofi in 2025 in billion-dollar deal.
• SanofiflagshipStrategic or Co-development PartnerGlobal pharmaceutical partner in $280 million Translational Science Hub partnership with Queensland Government. Sanofi mRNA Centre of Excellence collaborating with UQ researchers on vaccine development.
• Queensland GovernmentflagshipStrategic or Co-development PartnerPartner in $280 million Translational Science Hub and other initiatives. Provided funding support for bioscience infrastructure and research programs.
• BoeingcoreStrategic or Co-development PartnerPartnership for antiviral surface coating technology for aircraft. Boeing (BR&T-Australia) collaborated on COVID-19 surface coating development. Technology tested on International Space Station.
• GEcoreStrategic or Co-development PartnerPartner in advanced aviation biofuel project using sugarcane. Collaboration part of pivotal multi-partner initiative including Queensland Government, Mackay Sugar Ltd, and IOR Energy.
• Mackay Sugar LtdcoreStrategic or Co-development PartnerPartner in advanced aviation biofuel development from sugarcane biomass. Provides feedstock for sustainable fuel production research.
• AdvanCellcoreStrategic or Co-development PartnerPartnership with Australian clinical-stage radiopharmaceutical company developing novel cancer therapies. Collaboration through AMTAR hub targeting next-generation radiopharmaceuticals.
• RedflowcoreStrategic or Co-development PartnerPartnership through ARC Research Hub for Safe and Reliable Energy Storage to improve Zinc Bromine Module batteries for grid-scale energy storage.
• CSLcoreStrategic or Co-development PartnerOne of AIBN's roster of stakeholders and industry partners in the biotechnology sector.
• Dow ChemicalcoreStrategic or Co-development PartnerListed as one of AIBN's industry partners among globally recognised firms.
• Woodside PetroleumcoreStrategic or Co-development PartnerIndustry partner for sustainability research and bioeconomy transition initiatives.
• Evolution MiningcoreStrategic or Co-development PartnerPartner funding development of Immuno-storm chip diagnostic device for detecting cytokine storms in cancer and COVID-19 patients.
• Cassowary PharmacoreStrategic or Co-development PartnerAIBN spinout company developing hyper-targeted medications for chronic pain. Professor Trent Munro leads development. Funded by MRFF CUREator scheme ($40M national funding).
• HBIcoreStrategic or Co-development PartnerPartner for regenerative wound healing technology and preventing scar formation using biomaterials research.
• Griffith UniversityflagshipStrategic or Co-development PartnerPartner in $280 million Translational Science Hub alongside UQ and Translational Research Institute for mRNA vaccine and healthcare solution development.
• Australian Organoid Facility (AOF)coreStrategic or Co-development PartnerFacility housed at AIBN scaling up organoid production capability for personalized medicine research.
• National Biologics Facility (NBF)coreStrategic or Co-development PartnerNCRIS-funded facility housed at AIBN enabling translation of biomedical research discoveries to clinical supply.
• UniQuestflagshipImplementation/ SI/ Consulting PartnerUQ's commercialization company managing IP licensing, technology transfer, and spinout company creation including Vaxxas, Vicebio, and Cassowary Pharma.
• Clarity PharmaceuticalscoreStrategic or Co-development PartnerLong-standing partnership with Supply Agreement for radionuclide Copper-64, advancing cancer imaging and treatment research.
• AEGROScoreStrategic or Co-development PartnerPartner in plasma and therapies innovation through AIBN's industry innovator video series.
• ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals (AMTAR)flagshipStrategic or Co-development PartnerHub housed at AIBN with $5M ARC funding and $10M+ from partners. One-stop-shop for radiopharmaceutical innovation and streamlined emerging technologies.

Scale indicators14 records

Recent moves8 records

Expansion highlights5 records

Broad incumbents

• CSIRO (Commonwealth Scientific and Industrial Research Organisation): Australia's national science agency with overlapping capabilities in synthetic biology, biomanufacturing, biofuels, and advanced materials — directly comparable to AIBN's Biosustainability Hub and FaBA accelerator work.
• Karolinska Institutet: European medical research university with strong translational pipelines, large-scale vaccine and radiopharmaceutical research, and similar industry partnership and spinout models to AIBN.
• Peter MacCallum Cancer Centre: Australia's largest cancer research and treatment center with deep translational capability, including radiopharmaceuticals and theranostics that directly overlap with AIBN's AMTAR hub and AdvanCell/Telix partnerships.
• Broad Institute of MIT and Harvard: Larger international peer with a comparable model of co-located research platforms, large-scale genomics and chemical biology, and a strong spinout/licensing pipeline through a dedicated commercialization arm.
• The Francis Crick Institute: Large UK biomedical research institute with comparable scale (~1,500 scientists), co-located technology platforms and industry partnership model that mirror AIBN's translational research institute structure.
• Scripps Research Institute: Premier US biomedical research institute with deep expertise in molecular biology, vaccine development and structural biology — overlapping AIBN's molecular clamp, mRNA, and infectious disease research agendas.

Direct peers

• Walter and Eliza Hall Institute of Medical Research: Australia's oldest medical research institute, also based in Melbourne and embedded in a university (University of Melbourne). Comparable in mission, scale (~1,000+ researchers), government grant dependency, and pipeline of biotech spinouts.
• Garvan Institute of Medical Research: Sydney-based biomedical research institute affiliated with UNSW, with similar translational genomics, cancer therapeutics and immunology focus. Closest Australian analog by mission and funding model.
• Medicines Manufacturing Innovation Centre (MMIC) / CSIRO Biomedicine: Australian mRNA and biologics manufacturing capability competing with AIBN's BASE/NBF facilities for the same industry partners and government mRNA sovereign capability funding.
• Monash Biomedicine Discovery Institute: Monash University's flagship biomedical research institute with comparable size (~700 researchers), industry partnership model and translational mandate, including mRNA and infectious disease programs overlapping AIBN's BASE and molecular clamp work.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/AIBNatUQ
• YouTubeyoutube.com/user/AIBNatUQ
• Facebookfacebook.com/AIBNatUQ
• LinkedInlinkedin.com/company/aibnatuq

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Australian Institute for Bioengineering and Nanotechnology AIBN